Alexion 'Misled' USPTO About Blood Drug Patent, PTAB Says - Law360

Alexion ‘Misled’ USPTO About Blood Drug Patent, PTAB Says – Law360

Source Node: 3041154
By Ryan Lynch (December 21, 2023, 7:28 PM EST) -- The Patent Trial and Appeal Board has instituted review of an Alexion blood medication patent after finding that the company "misled" a U.S. Patent and Trademark Office examiner by providing "incomplete and inaccurate" information....

Time Stamp:

More from Law 360